InflaRx Announces Participation in September Investor Conferences
InflaRx (NASDAQ:IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3-5) with a fireside chat on September 4th at 9:10 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10) with a presentation on September 9th at 3:30 PM ET.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, and they are also developing INF904, an oral small molecule C5a receptor inhibitor.
InflaRx (NASDAQ:IFRX), azienda biofarmaceutica specializzata in terapie anti-infiammatorie, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2025. L'azienda interverrà al Cantor Global Healthcare Conference (3-5 settembre) con un fireside chat il 4 settembre alle 9:10 ET, e al H.C. Wainwright 27th Annual Global Investment Conference (8-10 settembre) con una presentazione il 9 settembre alle 15:30 ET.
InflaRx si concentra sullo sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore. Il loro prodotto di punta, vilobelimab, è un anticorpo monoclonale anti-C5a somministrato per via endovenosa, e stanno sviluppando anche INF904, un inibitore orale del recettore C5a a piccola molecola.
InflaRx (NASDAQ:IFRX), una compañía biofarmacéutica centrada en terapias antiinflamatorias, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025. La empresa presentará en el Cantor Global Healthcare Conference (3-5 de septiembre) con un fireside chat el 4 de septiembre a las 9:10 ET, y en el H.C. Wainwright 27th Annual Global Investment Conference (8-10 de septiembre) con una presentación el 9 de septiembre a las 15:30 ET.
InflaRx se especializa en desarrollar inhibidores del factor de activación del complemento C5a y de su receptor. Su producto principal, vilobelimab, es un anticuerpo monoclonal anti-C5a administrado por vía intravenosa, y también están desarrollando INF904, un inhibidor oral de pequeña molécula del receptor C5a.
InflaRx (NASDAQ:IFRX)는 항염증 치료제에 주력하는 바이오제약사로, 2025년 9월 두 건의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다. 회사는 Cantor Global Healthcare Conference(9월 3–5일)에서 9월 4일 오전 9시 10분(동부시간)에 파이어사이드 챗을 진행하고, H.C. Wainwright 27th Annual Global Investment Conference(9월 8–10일)에서는 9월 9일 오후 3시 30분(동부시간)에 발표할 예정입니다.
InflaRx는 보체 활성화 인자 C5a와 그 수용체의 억제제 개발을 전문으로 합니다. 주력 제품 vilobelimab은 정맥 주사형 항-C5a 단클론항체이며, 또한 경구용 소분자 C5a 수용체 억제제인 INF904를 개발 중입니다.
InflaRx (NASDAQ:IFRX), une société biopharmaceutique spécialisée dans les thérapies anti-inflammatoires, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025. La société interviendra au Cantor Global Healthcare Conference (3-5 septembre) avec un fireside chat le 4 septembre à 9h10 ET, et au H.C. Wainwright 27th Annual Global Investment Conference (8-10 septembre) avec une présentation le 9 septembre à 15h30 ET.
InflaRx se concentre sur le développement d'inhibiteurs du facteur d'activation du complément C5a et de son récepteur. Leur produit phare, vilobelimab, est un anticorps monoclonal anti-C5a administré par voie intraveineuse, et ils développent également INF904, un inhibiteur oral de petite molécule du récepteur C5a.
InflaRx (NASDAQ:IFRX), ein biopharmazeutisches Unternehmen mit Fokus auf entzündungshemmende Therapien, hat seine Teilnahme an zwei großen Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird auf der Cantor Global Healthcare Conference (3.–5. September) mit einem Fireside-Chat am 4. September um 9:10 Uhr ET vertreten sein und auf der H.C. Wainwright 27th Annual Global Investment Conference (8.–10. September) mit einer Präsentation am 9. September um 15:30 Uhr ET auftreten.
InflaRx spezialisiert sich auf die Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und seines Rezeptors. Ihr Leitprodukt, vilobelimab, ist ein intravenös verabreichtes Anti-C5a monoklonales Antikörper, und zudem entwickeln sie INF904, einen oralen Niedermolekül-Inhibitor des C5a-Rezeptors.
- None.
- None.
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows:
Cantor Global Healthcare Conference 2025
September 3 - 5, 2025 in New York, NY
Fireside chat on September 4th at 9:10 AM ET
InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here.
H.C. Wainwright 27th Annual Global Investment Conference
September 8 - 10, 2025 in New York, NY
Presentation on September 9th at 3:30 PM ET
InflaRx will also conduct one-on-one investor meetings on September 9th. A link to register for the presentation live stream and its replay is available here.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When is InflaRx (IFRX) presenting at the Cantor Global Healthcare Conference 2025?
What time is InflaRx's presentation at the H.C. Wainwright Conference 2025?
What are the main products being developed by InflaRx (IFRX)?
Where can investors access InflaRx's conference presentations?
What is InflaRx's therapeutic focus?
